Get the latest news alerts: at Twitter
Local Tech Wire
CHAPEL HILL, N.C. — Pozen Inc. (NASDAQ: POZN) said Friday that it has begun enrolling 1,000 patients across the country for two Phase III studies for its experimental drug for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.
The compound, PA32540, is a fixed-dose combination of 325 mg of enteric-coated aspirin and 40 mg of immediate-release omeprazole.
The two trials will operate under a special protocol assessment that Pozen and the federal Food and Drug Administration set up, Pozen said. The studies will involve over 100 sites, enrolling approximately 500 patients per study.
“We believe that PA32540 could address the needs of certain patients with cardiovascular disease,” said Dr. John Fort, Pozen’s chief medical officer.
